JPMorgan Chase & Co. Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

12 May 2026, 11:32 by Doug Wharley · The Cerbat Gem

Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price target reduced by analysts at JPMorgan Chase & Co. from $35.00 to $33.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 31.58% from the stock’s previous close.

HIMS has been the topic of a number of other research reports. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday. Canaccord Genuity Group set a $32.00 price target on shares of Hims & Hers Health in a report on Tuesday. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a report on Friday, March 27th. Barclays raised their price target on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, March 11th. Finally, Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday. Four analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average price target of $29.50.

Get Our Latest Stock Report on Hims & Hers Health

Hims & Hers Health Stock Down 13.9%

Shares of NYSE:HIMS traded down $4.06 during trading on Tuesday, reaching $25.08. 27,985,094 shares of the company traded hands, compared to its average volume of 33,140,680. The firm has a fifty day simple moving average of $23.08 and a 200 day simple moving average of $29.44. The firm has a market cap of $5.72 billion, a P/E ratio of 49.14, a price-to-earnings-growth ratio of 3.85 and a beta of 2.43. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.20 EPS. Analysts anticipate that Hims & Hers Health will post 0.53 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Michael Chi sold 97,289 shares of Hims & Hers Health stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $2,402,065.41. Following the transaction, the chief operating officer owned 407,282 shares in the company, valued at $10,055,792.58. This trade represents a 19.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the transaction, the chief financial officer owned 281,867 shares in the company, valued at $7,300,355.30. This trade represents a 11.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 204,857 shares of company stock worth $5,285,706. Insiders own 13.71% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Concurrent Investment Advisors LLC increased its holdings in shares of Hims & Hers Health by 1.8% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after purchasing an additional 252 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Hims & Hers Health by 44.7% during the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after purchasing an additional 283 shares during the period. W.G. Shaheen & Associates DBA Whitney & Co increased its holdings in shares of Hims & Hers Health by 4.8% during the 3rd quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company’s stock worth $436,000 after purchasing an additional 350 shares during the period. Sigma Planning Corp increased its holdings in shares of Hims & Hers Health by 1.5% during the 1st quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after purchasing an additional 388 shares during the period. Finally, BAM Wealth Management LLC increased its holdings in shares of Hims & Hers Health by 5.6% during the 4th quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock worth $240,000 after purchasing an additional 393 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Hims & Hers raised its 2026 revenue outlook and also guided Q2 revenue above Wall Street estimates, suggesting management still sees solid demand ahead. Hims & Hers Health (NYSE:HIMS) Misses Q1 CY2026 Sales Expectations, Stock Drops 11.5%
Positive Sentiment: Needham lifted its price target on HIMS to $35 from $30 and reiterated a Buy rating, signaling continued analyst confidence despite the weak quarter. Needham Raises Price Target on Hims & Hers Health
Neutral Sentiment: BTIG reaffirmed a Neutral rating, reflecting a mixed near-term view as investors weigh growth against earnings volatility. BTIG Reaffirms Neutral Rating on Hims & Hers Health
Neutral Sentiment: The company continues expanding its digital health platform with new care offerings, including labs, menopause, testosterone care, and international acquisitions, which supports the longer-term growth story. Hims & Hers Expands Digital Healthcare Platform via New Care Offerings
Negative Sentiment: Q1 results showed a $92.1 million loss and a revenue miss, with management blaming the GLP-1 transition for higher costs and weaker margins. Hims & Hers plunges after weight-loss pivot hits quarterly results
Negative Sentiment: The sharp sell-off reflects investor disappointment that the quarter did not meet expectations after a strong run-up in the share price. Hims & Hers Stock Sinks. Why Earnings Offered Wall Street A Big Surprise.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.